CBD-based Solutions for Treating Dyslipidemia
CannaLean Biotechs is committed to the research and development of a proprietary formulation of cannabidiol (CBD) and chitosan that can potentially benefit millions of patients with dyslipidemia.
CannaLean uses a synthetic form of CBD, a non-psychotropic component of cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to reduce lipid blood levels. The company’s preliminary results show the effect of the formulation on cholesterol and triglyceride
Israel Trade and Economic Commission Sydney, Australia 